Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Markers of Efficacy of Xolair (Omalizumab) in Chronic Spontaneous Urticaria
2014-005127-27Phase 4Active
- Sponsor
- University Medical Center Utrecht
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of omalizumab in chronic idiopathic urticaria (CIU), sponsored by University Medical Center Utrecht. Primary endpoint: Reduction of inflammatory characteristics in the skin. Started May 2015; status: active.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2014-005127-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005127-27.